Journal
NEURO-ONCOLOGY
Volume 13, Issue 4, Pages 401-409Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/neuonc/noq206
Keywords
MRI; glioblastoma; bevacizumab; volumetric analysis
Categories
Funding
- Brain Tumor Funders Collaborative
- Art of the Brain
- Ziering Family Foundation in memory of Sigi Ziering
- Singleton Family Foundation
- Clarence Klein Fund for Neuro-Oncology
Ask authors/readers for more resources
Although the effects of bevacizumab on magnetic resonance images (MRIs) of recurrent glioblastoma multi-forme (GBM) are well documented, to our knowledge, no studies have explicitly quantified the volumetric changes resulting from initial treatment, nor have there been studies examining the ability for volumetric changes in conventional MRI to predict progression-free survival (PFS) and overall survival (OS). In the current study, we retrospectively examined volumetric changes on conventional MRI scans in 84 patients with recurrent GBM. MRIs were obtained before (mean, 11 days) and after (mean, 42 days) treatment with bevacizumab. The volume of abnormal fluid-attenuated inversion recovery (FLAIR) signal intensity, the volume of contrast enhancement, and the ratio of the 2 were quantified for each patient before and after initial treatment. Results demonstrated that initial treatment with bevacizumab resulted in a significant decrease in both the volume of abnormal FLAIR signal and the volume of contrast enhancement. Initial, residual, and change in FLAIR volume were not predictive of PFS or OS. Initial contrast-enhancing volume was predictive of PFS but not OS. The pretreatment relative nonenhancing tumor ratio, defined as the ratio of FLAIR to contrast-enhancing volume, was found to be predictive of both PFS and OS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available